PT-141 (Bremelanotide)
Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
Typical daily range: 500–1500 mcg once daily (gradual titration over 16 weeks).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Goal: Support sexual desire and arousal through central melanocortin receptor activation.
Frequency: Inject once daily subcutaneously.
| Phase | Dose | Syringe (U-100) |
|---|---|---|
| Weeks 1–8 | 500 mcg (0.5 mg) | 15 units (0.15 mL) |
| Weeks 9–12 | 1000 mcg (1.0 mg) | 30 units (0.30 mL) |
| Weeks 13–16 | 1500 mcg (1.5 mg) | 45 units (0.45 mL) |
PT-141 (bremelanotide) is a melanocortin receptor agonist (primarily MC4R activity) developed for sexual dysfunction. Clinically, bremelanotide is FDA-approved (brand: Vyleesi) for premenopausal hypoactive sexual desire disorder (HSDD). Unlike PDE5 inhibitors, PT-141 works centrally (brain pathways) rather than directly on penile vasodilation.
- Improved sexual desire and reduced distress in women with HSDD (clinical trials).
- Increased arousal response in some study settings.
- Possible utility in select erectile dysfunction contexts (research/clinical investigation).
- Central mechanism may benefit individuals who do not respond to PDE5 inhibitors (research context).
- Nausea (common; can be dose-limiting).
- Flushing and warmth.
- Headache.
- Increased blood pressure / decreased heart rate (transient).
- Injection site reactions (if subcutaneous).
- Hyperpigmentation with repeated use has been reported for melanocortin agonists.
- Uncontrolled hypertension or known cardiovascular disease risk where transient BP increases are unsafe.
- Pregnancy or breastfeeding (avoid; insufficient safety data).
- Concomitant drugs where BP/HR changes are a concern (medical review required).
- History of severe nausea/vomiting with melanocortin agonists.
- PT-141 is often discussed alongside PDE5 inhibitors (e.g., sildenafil) in research conversations; any combination should be clinician-supervised due to blood pressure considerations.
- Lifestyle foundations (sleep, stress management) often have outsized effect vs. stacking multiple compounds.
- Kingsberg SA et al. Obstet Gynecol. 2019. PMID: 31779145
- Clayton AH et al. J Sex Med. 2019. PMID: 31571272
- Derogatis LR et al. J Womens Health (Larchmt). 2019. PMID: 30953309
- Diamond LE et al. J Sex Med. 2011. PMID: 21452101
- Wessells H et al. J Urol. 2006. PMID: 16870167
- Dorr RT. Clin Pharmacol Ther. 2000. PMID: 10840086
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).